Medication-Induced DyskinesiaPhase 2NCT05148884
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
A Phase 2 study testing NLX-112 in people with Medication-Induced Dyskinesia, run by Neurolixis SAS at 5 sites in Sweden.
Trial summary
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). Read more about this study
- Who is it for?
- Ages 30 to 85 years
- Conditions the study is for
- Medication-Induced Dyskinesia
- What is being tested?
- NLX-112
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 27 participants
- Where
- 5 sitesSweden
- Study dates
- 9 Nov 2021to 18 Jan 2023
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patient is 30 - 85 years old (inclusive) with a diagnosis of idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis criteria.
- PD patient is stably and optimally treated with L-DOPA; other anti-PD treatments are allowed if used for at least 4 weeks of previous continuous treatment.
- Patient agrees to be challenged with 150% of their normal L-DOPA dose (maximum L-DOPA dose 250 mg) 30 minutes prior to efficacy assessments at baseline (Visit 2) and at the 2 efficacy clinic visits (Visits 6 and 7).
- PD patient exhibits troublesome peak-dose LID, confirmed by a score of at least 1 on part IV, item 33 (disability) of the UPDRS at screening (Visit 1) and at Day 1 (baseline, Visit 2).
- At least 90 minutes in total for each 24-hour period during 2 days are indicated as "ON with troublesome dyskinesia" (according to the PD Home Dyskinesia Diary) prior to Day 1 (baseline, Visit 2).
- Patient (and/or caregiver) demonstrates ability to accurately complete the PD Home Dyskinesia Diary entries during the screening visit.
Show all 10Show fewer
- Patient can read well enough to understand the informed consent document and other subject materials.
- Female patients of child-bearing potential must have a negative urine pregnancy test at screening (Visit 1) and on Day 1 (Visit 2), must agree to avoid pregnancy during the study, and must practice abstinence (only allowed when this is the preferred and usual lifestyle of the subject) or must agree to use a highly effective method of contraception with a failure rate of < 1% to prevent pregnancy (combined [oestrogen and progestogen containing] hormonal contraception associated with inhibition of ovulation [oral, intravaginal, transdermal], progestogen-only hormonal contraception associated with inhibition of ovulation [oral, injectable, implantable], intrauterine device [IUD] or intrauterine hormone-releasing system [IUS]) starting from 4 weeks prior to administration of the study drug and continuing during the course of the study until 4 weeks after last after IMP administration. Female subjects must agree to refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner must agree to use a condom during the same time frame if he has not undergone vasectomy.
- Females of non-childbearing potential are defined as pre-menopausal females who are sterilised (tubal ligation or permanent bilateral occlusion of fallopian tubes); or females who have undergone hysterectomy or bilateral oophorectomy; or post-menopausal defined as 12 months of amenorrhea (in questionable cases a blood sample with detection of follicle stimulating hormone [FSH] 25-140 IE/L is confirmatory).
- Male patients must be either vasectomised, consent to use condom or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. Their female partner of child-bearing potential must use highly effective contraceptive methods with a failure rate of < 1% to prevent pregnancy (see above) during the same period.
Who cannot join
- Patient has severe PD with a Hoehn and Yahr stage = 5.
- Patient has unstable medical status, prior brain surgery against tumors or hemorrhage (excluding deep brain stimulation [DBS], i.e., DBS patients will be allowed to be enrolled) or is scheduled to receive surgery during the trial period.
- Patient has orthostatic hypotension: a decrease in systolic blood pressure (at least 20 mm Hg) or diastolic blood pressure (at least 10 mm Hg) within 3 minutes of the patient standing up, compared to pressures obtained while in a sitting position for at least 5 minutes. At screening and baseline visits (Visit 1 and Visit 2), vital signs to assess orthostatic hypotension will be conducted in triplicate, 15-20 minutes apart, with the average of the 3 assessments used for exclusion.
- Patient has dementia (MMSE <20).
- Patient has clinically significant renal or liver disorder.
- Patient currently exhibits generalized obsessive-compulsive disorder, panic disorder, bipolar disorder, post-traumatic stress syndrome (PTSD), clinically significant parasomnias or any other psychotic disorder as established by structured clinical interview for DSM disorders (SCID). Visual hallucinations are allowed.
Show all 12Show fewer
- Any suicidal actions in the past 2 years (per investigator judgement i.e. actual attempt, interrupted attempt, aborted attempt, or preparatory acts or behavior).
- Any suicidal ideation of type 4 or 5 in the C-SSRS in the past 3 months (i.e. active suicidal thought with intent but without specific plan, or active suicidal thought with plan and intent).
- Patient has taken an anti-convulsant, an anti-psychotic (except quetiapine), pindolol, tertatolol or buspirone within 4 weeks of baseline (Day 1, Visit 2).
- Patient has taken any medication, within 4 weeks of baseline (Day 1, Visit 2) that inhibits or up-regulates CYP4503A4.
- Patient is concurrently participating in another investigational drug trial or has participated in another investigational drug trial within the past 3 months.
- Patient is at high risk of non-compliance in the Investigator's opinion.
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Sweden5 sites
Sahlgrenska Hospital
Gothenburg, 413 45
Skåne University Hospital
Lund, 221 85
ASC Torsplan
Stockholm, 113 65
Karolinska University Hospital, Solna
Stockholm, 171 76
CTC Clinical Trial Consultants AB (CTC)
Uppsala, 752 37
About this study
Official title: A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.
Read the detailed description
This is a two-arm, double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day of NLX 112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day (1 mg BID) or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.
Patients will report to the study clinic for a screening visit (Visit 1), followed by a baseline visit on Day 1 (Visit 2) where patients will be randomized and begin treatment. Two remote safety visits over telephone (Days 7 and 49 [Visit 3 and Visit 8]) will be conducted. Once treatment has commenced, there will be 2 in-person safety visits to the clinic (Days 14 and 21 [Visit 4 and Visit 5]), 2 in-person efficacy visits to the clinic (Days 28 and 42 [Visit 6 and Visit 7]) and one follow-up in person final safety visit (Day 70 [Visit 9]). In total, patients will report to the clinic for 7 in-person visits. Patients entering the study will be randomized in a 2:1 ratio (16:8 patients) to receive either NLX 112 or placebo.
At Visits 2, 6 and 7, efficacy assessments will start 30 minutes after the patient has taken 150% of his or her regular L-DOPA dose, when the patient is ON and experiencing typical dyskinesia.
A PD Home Dyskinesia Diary (electronic) will be completed by the patients and/or caregiver with concordance in ON time with dyskinesia between study staff and patient. Two consecutive 24-hour diaries will be completed prior to randomization (baseline, Visit 2) and prior to the clinic visits on Days 28 and 42 (Visits 6 and 7).
A wearable dyskinesia assessment device will be used to monitor dyskinesias during a 2-day period prior to the baseline visit (Day 1, Visit 2) and a 2-day period prior to the clinic visits on Days 28 and 42 (Visits 6 and 7, respectively).
Blood will be collected for possible NLX-112 plasma concentration measurements on Days 14, 21, 28, 42 and 70 (Visits 4, 5, 6, 7 and 9).
- Conditions
- Medication-Induced Dyskinesia
- Being tested
- NLX-112, Placebo
- Keywords
- Levodopa, Dyskinesia, Parkinson´s disease, L-dopa, NLX-112, Befiradol, LID
- Medical subject headings
- Dyskinesia, Drug-Induced, Dyskinesias, Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NLX-112Drug
Also called F13640, befiradol, 4-piperidinemethanamine, 1-(3-chloro-4-fluorobenzoyl)-4-fluoro-N-[(5-methyl-2-pyridinyl)-methyl]
NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease.
PlaceboDrug
Placebo will be matching tablets (identical weight, shape and color) without NLX-112.
| Study group | Role | What they receive |
|---|---|---|
| NLX-112 | Experimental | Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks. Receives: Drug: NLX-112 |
| Placebo | Placebo comparator | Patients will self-administer placebo 2 times each day, once in the morning and once in the evening. Up-titration of number of tablets over 4 weeks, number of tablets equivalent to maximal dose of 2 mg/day NLX-112 during 2 weeks, down-titration over 2 weeks. Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Adverse Events (AEs)
Number of patients with Adverse events (AEs) divided into categories of severity/intensity (grade 1 to grade 5 following the common terminology criteria for AEs (CTCAE) v5.0) and assessed relationship to IMP (unlikely, possibly or probably related). AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit.
Measured: AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit. Through study completion, an average of 10 weeks.
Number of Participants With Any Clinically Significant Changes From Baseline in Electrocardiogram (ECG)
Number of patients with clinically significant changes from baseline in Electrocardiogram (Rate, PR interval, QRS duration, QT, QTcB, and QTcF). Any abnormalities were specified and documented as either clinically significant or not clinically significant.
Measured: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of Patients With Any Clinically Significant Changes From Baseline in Vital Signs
Number of patients with clinically significant changes from baseline in vital signs (Systolic blood pressure (mmHg), diastolic blood pressure (mmHg), Heart rate, respiratory rate, body temperature). Any vital signs outside the normal ranges at each site were judged as either not clinically significant or clinically significant by the clinician.
Measured: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of Patients With Any Clinically Significant Changes From Baseline in Safety Laboratory Parameters
Number of patients with clinically significant changes from baseline in safety laboratory parameters. Any lab values outside the normal ranges at each site were judged as not clinically significant or clinically significant.
Measured: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of Patients With Clinically Significant Abnormalities in Physical Examinations
Number of patients with clinically significant abnormalities in physical examination investigated by general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Any abnormalities were specified and documented as either clinically significant or not clinically significant.
Measured: Visit 1 (Screening) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of Patients With Suicidal Ideation/Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Number of patients with change from baseline in suicidal ideation/behavior as assessed by C-SSRS questionnaire with no total score summation. The scale contains 6 "yes" or "no" questions in which respondents were asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past 3 months and behavior over their lifetime using a baseline scale at visit 1 and any cahnges since last visit using a follow-up scale at subsequent visits. Each question addresses a different component of the respondent's suicide ideation severity and behavior. Q1: wish to be dead, Q2: non-specific suicidal thoughts, Q3-5: more specific suicidal thoughts and intent to act, Q6: suicidal behavior over the respondent's lifetime and past 3 months or since last visit for visits after the visit 1.
Measured: The baseline scale was used at screening (Visit 1) and the follow-up scale at all subsequent visits (Visit 2, 4-7, 9)
Secondary outcomes (8)
Change From Baseline at the Final Efficacy Clinic Visit (Day 42), After a 150% L-dopa Dose Challenge, in the Unified Dyskinesia Rating Scale (UDysRS) Total Score - Change From Baseline
The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:
- Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).
- Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).
- Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).
- Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).
Each item in the UDysRS was scored from 0 to 4, with a possible maximum total score sum of 104 where a higher score indicates a worse outcome.
The UDysRS Parts 3 and 4 were repeated 3 times after each L-dopa challenge, and the timepoint with the worst outcome was used to calculate total score sum
Measured: At baseline (Day 1, Visit 2), and Day 42 (Visits 7)
Change From Baseline in UDysRS Total Score at Day 28, After a 150% L-DOPA Dose Challenge - Change From Baseline
The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:
- Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).
- Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).
- Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).
- Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).
Each item in the UDysRS was scored from 0 to 4, with a possible maximum total score sum of 104 where a higher score indicates a worse outcome.
The UDysRS Parts 3 and 4 were repeated 3 times after each L-dopa challenge, and the timepoint with the worst outcome was used to calculate total score sum
Measured: At baseline (Day 1, Visit 2) and Day 28 (Visits 6)
Change From Baseline in Total Objective Score (Parts 3, 4) of the UDysRS at Day 28 and Day 42, After a 150% L-DOPA Dose Challenge - Change From Baseline
The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:
- Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).
- Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).
- Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).
- Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).
Each item in the UDysRS was scored from 0 to 4, with a possible total score sum for parts 3 and 4 of 44, where a higher score indicates a worse outcome.
The UDysRS Parts 3 and 4 were repeated 3 times after each levodopa challenge, and the timepoint with the worst outcome was used to calculate total score sum.
Measured: At baseline (Day 1, Visit 2), Day 28 and Day 42 (Visits 6 and 7)
Change From Baseline in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) Based on a PD Home Dyskinesia Diary - Change From Baseline
A PD Home Dyskinesia Diary (electronic) as completed by the patient and/or caregiver with concordance in ON time with dyskinesia between study staff and patient. The diary was integrated in the Kinesia 360 wearable dyskinesia assessment system and was based on the PD Home Diary developed by Hauser et al 2004. The diary was used to score 5 different conditions in 30-minute time intervals during 2x24 hours prior to Visit 2 (Baseline), Visit 6 (Titration) and Visit 7 (Steady state):
- ASLEEP;
- OFF;
- ON (i.e., adequate control of PD symptoms) without dyskinesia;
- ON with non-troublesome dyskinesia;
- ON with troublesome dyskinesia.
Presented as the ratio of ON Time without troublesome dyskinesia (the sum of the time in ON without dyskinesia together with the time in ON with non-troublesome dyskinesia) compared with the total awake time (ON and OFF).
Measured: Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Scores (Part III, Motor Examination) - Change From Baseline
The UPDRS is one of the most widely-used rating scales employed in the assessment of PD. The UPDRS consists of 4 parts:
- Part I assesses non-motor experiences of daily living, such as cognitive impairment and depressed mood (4 items).
- Part II assesses motor experiences of daily living, such as speech and eating tasks (13 items).
- Part III is a motor examination conducted by the clinician, including assessments of symptoms such as rigidity and tremor (27 items).
- Part IV is an assessment of motor complications, such as time spent with dyskinesia and functional impact of dyskinesias (11 items).
Each item in the UPDRS was scored from 0 to 4 (7 items in Part IV was scored 0 to 1), and the individual scores were summed to give a total score that indicates the severity of the disease, with a score of 0 indicating no disability and a score of 199 being the most severe (indicating total disability). Total score sum for Part III alone is 108.
Measured: At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).
Change From Baseline in UPDRS Combined Scores (Parts I, II, III and IV) - Change From Baseline
The UPDRS is one of the most widely-used rating scales employed in the assessment of PD. The UPDRS consists of 4 parts:
Part I assesses non-motor experiences of daily living, such as cognitive impairment and depressed mood (4 items).
Part II assesses motor experiences of daily living, such as speech and eating tasks (13 items).
Part III is a motor examination conducted by the clinician, including assessments of symptoms such as rigidity and tremor (27 items).
Part IV is an assessment of motor complications, such as time spent with dyskinesia and functional impact of dyskinesias (11 items).
Each item in the UPDRS was scored from 0 to 4 (7 items in Part IV was scored 0 to 1), and the individual scores were summed to give a total score that indicates the severity of the disease, with a score of 0 indicating no disability and a score of 199 being the most severe (indicating total disability).
Measured: At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).
Number of Patients in Each Category of Clinical Global Impression of Change (CGI-C) in Overall PD Symptoms
The CGI-C is a clinician-oriented scale that assesses the total improvement in the patient's condition relative to the clinical global impression of severity (CGI-S) scale conducted at baseline.
1 - Normal not ill, 2 - Borderline ill, 3 - Mildly ill, 4 - Moderately ill, 5 - Markedly ill, 6- Severely ill, 7 - Among the most extremely ill patients The CGI-C rates the patient's condition from 1 to 7: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse
Measured: Clinician rated the patient´s global condition using CGI-S at baseline (Day 1, Visit 2) and CGI-C at Day 28 (Visit 6) and Day 42 (Visit 7).
Change From Baseline in Dyskinesia Scores Measured by the Kinesia 360 (Great Lakes Neurotechnologies, Inc) Wearable Dyskinesia Assessment System - Absolute Change From Baseline
The Kinesia 360 (Great Lakes Neurotechnologies, Inc) wearable dyskinesia assessment system was used to monitor dyskinesias. Sensors worn on the wrist and ankle combined with a mobile application continuously record data for assessment dyskinesia. Algorithms were used to detect symptoms from the motion sensors data and calculate a severity score (0 to 1 where score 0 corresponds to no dyskinesia and score 1 corresponds to dyskinesia) every 2 minutes. Wearable data collection of dyskinesia took place during a 2-day period prior to Visit 2 (Baseline), Visit 6 (Titration) and Visit 7 (Steady state). Outcome is presented as the mean ratio at baseline and absolute ratio change from baseline.
Measured: Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Dec 2021
- Study start9 Nov 2021
- Primary completion18 Jan 2023
- Study completion18 Jan 2023
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Medication-Induced DyskinesiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Double-blind, randomized, placebo-controlled Phase 2a study
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 27 participants (actual)
Sponsor and investigators
- Lead sponsor
- Neurolixis SAS
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Parkinson's UK, CTC Clinical Trial Consultants AB
- Responsible party
- Sponsor
- Investigators
- Adrian Newman-Tancredi, PhD, Study director, Neurolixis SASPer Svenningsson, Professor, Principal investigator, ASC Torsplan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05148884
- Sponsor's protocol ID
- NLX-112-DYS-101
- Status last verified
- Mar 2024
- First submitted
- 7 Oct 2021
- Last updated
- 23 Apr 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease
- ClinicalTrials.gov ID
- NCT05148884
- Acronym / sponsor ID
- NLX-112-DYS-101
- Conditions
- Medication-Induced Dyskinesia
- Keywords
- Levodopa, Dyskinesia, Parkinson´s disease, L-dopa, NLX-112, Befiradol, LID
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 27 participants (actual)
- Lead sponsor
- Neurolixis SASIndustry (pharma, biotech, devices)
- Collaborators
- Michael J. Fox Foundation for Parkinson's Research, Parkinson's UK, CTC Clinical Trial Consultants AB
- Study start
- 9 Nov 2021 (actual)
- Primary completion
- 18 Jan 2023 (actual)
- Study completion
- 18 Jan 2023 (actual)
- First posted
- 8 Dec 2021 (actual)
- Results
- Posted 23 Apr 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day (1 mg BID) of NLX-112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.
Detailed description
This is a two-arm, double-blind, randomized, placebo-controlled Phase 2a study evaluating the safety, tolerability, and preliminary efficacy of up to 2 mg/day of NLX 112 versus placebo in patients with moderate to severe L-DOPA induced dyskinesia (LID) in Parkinson's disease (PD). NLX-112 will be up-titrated to either 2 mg/day (1 mg BID) or to the highest well-tolerated dose less than 2 mg/day over 4 weeks, maintained at the well-tolerated dose for an additional 2 weeks, and then down-titrated over 2 weeks.
Patients will report to the study clinic for a screening visit (Visit 1), followed by a baseline visit on Day 1 (Visit 2) where patients will be randomized and begin treatment. Two remote safety visits over telephone (Days 7 and 49 [Visit 3 and Visit 8]) will be conducted. Once treatment has commenced, there will be 2 in-person safety visits to the clinic (Days 14 and 21 [Visit 4 and Visit 5]), 2 in-person efficacy visits to the clinic (Days 28 and 42 [Visit 6 and Visit 7]) and one follow-up in person final safety visit (Day 70 [Visit 9]). In total, patients will report to the clinic for 7 in-person visits. Patients entering the study will be randomized in a 2:1 ratio (16:8 patients) to receive either NLX 112 or placebo.
At Visits 2, 6 and 7, efficacy assessments will start 30 minutes after the patient has taken 150% of his or her regular L-DOPA dose, when the patient is ON and experiencing typical dyskinesia.
A PD Home Dyskinesia Diary (electronic) will be completed by the patients and/or caregiver with concordance in ON time with dyskinesia between study staff and patient. Two consecutive 24-hour diaries will be completed prior to randomization (baseline, Visit 2) and prior to the clinic visits on Days 28 and 42 (Visits 6 and 7).
A wearable dyskinesia assessment device will be used to monitor dyskinesias during a 2-day period prior to the baseline visit (Day 1, Visit 2) and a 2-day period prior to the clinic visits on Days 28 and 42 (Visits 6 and 7, respectively).
Blood will be collected for possible NLX-112 plasma concentration measurements on Days 14, 21, 28, 42 and 70 (Visits 4, 5, 6, 7 and 9).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Double-blind, randomized, placebo-controlled Phase 2a study
| Arm | Type | Receives |
|---|---|---|
| NLX-112 | Experimental | Drug: NLX-112Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks. |
| Placebo | Placebo comparator | Drug: PlaceboPatients will self-administer placebo 2 times each day, once in the morning and once in the evening. Up-titration of number of tablets over 4 weeks, number of tablets equivalent to maximal dose of 2 mg/day NLX-112 during 2 weeks, down-titration over 2 weeks. |
Who may qualify
- Ages
- 30 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Patient is 30 - 85 years old (inclusive) with a diagnosis of idiopathic PD according to the UK Parkinson's Disease Society Brain Bank Clinical Diagnosis criteria.
- PD patient is stably and optimally treated with L-DOPA; other anti-PD treatments are allowed if used for at least 4 weeks of previous continuous treatment.
- Patient agrees to be challenged with 150% of their normal L-DOPA dose (maximum L-DOPA dose 250 mg) 30 minutes prior to efficacy assessments at baseline (Visit 2) and at the 2 efficacy clinic visits (Visits 6 and 7).
- PD patient exhibits troublesome peak-dose LID, confirmed by a score of at least 1 on part IV, item 33 (disability) of the UPDRS at screening (Visit 1) and at Day 1 (baseline, Visit 2).
- At least 90 minutes in total for each 24-hour period during 2 days are indicated as "ON with troublesome dyskinesia" (according to the PD Home Dyskinesia Diary) prior to Day 1 (baseline, Visit 2).
Key exclusion criteria (12 listed)
- Patient has severe PD with a Hoehn and Yahr stage = 5.
- Patient has unstable medical status, prior brain surgery against tumors or hemorrhage (excluding deep brain stimulation [DBS], i.e., DBS patients will be allowed to be enrolled) or is scheduled to receive surgery during the trial period.
- Patient has orthostatic hypotension: a decrease in systolic blood pressure (at least 20 mm Hg) or diastolic blood pressure (at least 10 mm Hg) within 3 minutes of the patient standing up, compared to pressures obtained while in a sitting position for at least 5 minutes. At screening and baseline visits (Visit 1 and Visit 2), vital signs to assess orthostatic hypotension will be conducted in triplicate, 15-20 minutes apart, with the average of the 3 assessments used for exclusion.
- Patient has dementia (MMSE <20).
- Patient has clinically significant renal or liver disorder.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NLX-112Also: F13640, befiradol, 4-piperidinemethanamine, 1-(3-chloro-4-fluorobenzoyl)-4-fluoro-N-[(5-methyl-2-pyridinyl)-methyl]NLX-112 will be supplied as tablets containing 0.25 mg NLX-112. NLX-112 is a structurally novel centrally acting, high-efficacy selective 5-HT1A receptor agonist with nanomolar affinity for 5-HT1A receptors. Proposed as a treatment for L-DOPA-induced-dyskinesia in Parkinson's disease. | Drug | NLX-112 |
| PlaceboPlacebo will be matching tablets (identical weight, shape and color) without NLX-112. | Drug | Placebo |
Primary outcome
Number of Participants With Adverse Events (AEs)
Time frame: AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit. Through study completion, an average of 10 weeks.
Number of patients with Adverse events (AEs) divided into categories of severity/intensity (grade 1 to grade 5 following the common terminology criteria for AEs (CTCAE) v5.0) and assessed relationship to IMP (unlikely, possibly or probably related). AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit.
Number of Participants With Any Clinically Significant Changes From Baseline in Electrocardiogram (ECG)
Time frame: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of patients with clinically significant changes from baseline in Electrocardiogram (Rate, PR interval, QRS duration, QT, QTcB, and QTcF). Any abnormalities were specified and documented as either clinically significant or not clinically significant.
Number of Patients With Any Clinically Significant Changes From Baseline in Vital Signs
Time frame: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of patients with clinically significant changes from baseline in vital signs (Systolic blood pressure (mmHg), diastolic blood pressure (mmHg), Heart rate, respiratory rate, body temperature). Any vital signs outside the normal ranges at each site were judged as either not clinically significant or clinically significant by the clinician.
Number of Patients With Any Clinically Significant Changes From Baseline in Safety Laboratory Parameters
Time frame: Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of patients with clinically significant changes from baseline in safety laboratory parameters. Any lab values outside the normal ranges at each site were judged as not clinically significant or clinically significant.
Number of Patients With Clinically Significant Abnormalities in Physical Examinations
Time frame: Visit 1 (Screening) and Visit 9 (Follow-up Clinic Visit, Day 70).
Number of patients with clinically significant abnormalities in physical examination investigated by general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Any abnormalities were specified and documented as either clinically significant or not clinically significant.
Number of Patients With Suicidal Ideation/Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)
Time frame: The baseline scale was used at screening (Visit 1) and the follow-up scale at all subsequent visits (Visit 2, 4-7, 9)
Number of patients with change from baseline in suicidal ideation/behavior as assessed by C-SSRS questionnaire with no total score summation. The scale contains 6 "yes" or "no" questions in which respondents were asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past 3 months and behavior over their lifetime using a baseline scale at visit 1 and any cahnges since last visit using a follow-up scale at subsequent visits. Each question addresses a different component of the respondent's suicide ideation severity and behavior. Q1: wish to be dead, Q2: non-specific suicidal thoughts, Q3-5: more specific suicidal thoughts and intent to act, Q6: suicidal behavior over the respondent's lifetime and past 3 months or since last visit for visits after the visit 1.
8 secondary outcomes
Change From Baseline at the Final Efficacy Clinic Visit (Day 42), After a 150% L-dopa Dose Challenge, in the Unified Dyskinesia Rating Scale (UDysRS) Total Score - Change From Baseline
Time frame: At baseline (Day 1, Visit 2), and Day 42 (Visits 7)
Change From Baseline in UDysRS Total Score at Day 28, After a 150% L-DOPA Dose Challenge - Change From Baseline
Time frame: At baseline (Day 1, Visit 2) and Day 28 (Visits 6)
Change From Baseline in Total Objective Score (Parts 3, 4) of the UDysRS at Day 28 and Day 42, After a 150% L-DOPA Dose Challenge - Change From Baseline
Time frame: At baseline (Day 1, Visit 2), Day 28 and Day 42 (Visits 6 and 7)
Change From Baseline in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) Based on a PD Home Dyskinesia Diary - Change From Baseline
Time frame: Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Scores (Part III, Motor Examination) - Change From Baseline
Time frame: At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).
Change From Baseline in UPDRS Combined Scores (Parts I, II, III and IV) - Change From Baseline
Time frame: At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).
Number of Patients in Each Category of Clinical Global Impression of Change (CGI-C) in Overall PD Symptoms
Time frame: Clinician rated the patient´s global condition using CGI-S at baseline (Day 1, Visit 2) and CGI-C at Day 28 (Visit 6) and Day 42 (Visit 7).
Change From Baseline in Dyskinesia Scores Measured by the Kinesia 360 (Great Lakes Neurotechnologies, Inc) Wearable Dyskinesia Assessment System - Absolute Change From Baseline
Time frame: Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: No
Related trials for Medication-Induced Dyskinesia
Not yet recruitingPhase 1
Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia
Dyskinesia, Medication-induced, Dyskinesia, Drug-Induced
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
RecruitingPhase 4
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Schizophrenia, Schizoaffective Disorder
Recruiting
rTMS as an Intervention for Levodopa-induced Dyskinesia
Dyskinesia, Drug-Induced, Parkinson Disease
Enrolling by invitation
Neural Mechanisms of Clinically Designed Improvisatory Music for Alzheimer's Disease
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Adrian Newman-Tancredi, PhD study director
Neurolixis SAS
Per Svenningsson, Professor principal investigator
ASC Torsplan
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing NLX-112 in people with Medication-Induced Dyskinesia, run by Neurolixis SAS at 5 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Apr 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Adverse Events (AEs) (time frame: AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit. Through study completion, an average of 10 weeks.). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2024.